|
1
|
Hatzimichael E, Dasoula A, Benetatos L,
Syed N, Dranitsaris G, Crook T and Bourantas K: Study of specific
genetic and epigenetic variables in multiple myeloma. Leuk
Lymphoma. 51:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richards T and Weber D: Advances in
treatment for relapses and refractory multiple myeloma. Med Oncol.
27(Suppl 1): S25–S42. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laubach JP, Richardson PG and Anderson KC:
The evolution and impact of therapy in multiple myeloma. Med Oncol.
27:S1–S6. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khanna A, Böckelman C, Hemmes A, Junttila
MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C,
et al: MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnson MD, Reeder JE, O'Connell M,
Woodford M and Walter K: CIP2A and PP2A in human leptomeninges,
arachnoid granulations and meningiomas. J Clin Neurosci.
21:2228–2232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li W, Ge Z, Liu C, Liu Z, Björkholm M, Jia
J and Xu D: CIP2A is overexpressed in gastric cancer and its
depletion leads to impaired clonogenicity, senescence, or
differentiation of tumor cells. Clin Cancer Res. 14:3722–3728.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi YA, Park JS, Park MY, Oh KS, Lee MS,
Lim JS, Kim KI, Kim KY, Kwon J, Yoon do Y, et al: Increase in CIP2A
expression is associated with doxorubicin resistance. FEBS Lett.
585:755–760. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Terpos E, Morgan G, Dimopoulos MA, Drake
MT, Lentzsch S, Raje N, Sezer O, García-Sanz R, Shimizu K, Turesson
I, et al: International myeloma working group recommendations for
the treatment of multiple myeloma-related bone disease. J Clin
Oncol. 31:2347–2357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nasri M, Karimi A and Allahbakhshian
Farsani M: Production, purification and titration of a
lentivirus-based vector for gene delivery purposes. Cytotechnology.
66:1031–1038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhan F, Huang Y, Colla S, Stewart JP,
Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B,
et al: The molecular classification of multiple myeloma. Blood.
108:2020–2028. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pang X, Fu X, Chen S, Zhu X, Qi H, Li Y,
Li F and Tan W: Overexpression of CIP2A promotes bladder cancer
progression by regulating EMT. Clin Transl Oncol. 18:289–295. 2016.
View Article : Google Scholar
|
|
13
|
Khanna A, Rane JK, Kivinummi KK, Urbanucci
A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V,
Pimanda JE, et al: CIP2A is a candidate therapeutic target in
clinically challenging prostate cancer cell populations.
Oncotarget. 6:19661–19670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ventelä S, Sittig E, Mannermaa L, Mäkelä
JA, Kulmala J, Löyttyniemi E, Strauss L, Cárpen O, Toppari J,
Grénman R and Westermarck J: CIP2A is an Oct4 target gene involved
in head and neck squamous cell cancer oncogenicity and
radioresistance. Oncotarget. 6:144–158. 2015.
|
|
15
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De P, Carlson J, Leyland-Jones B and Dey
N: Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A
(CIP2A): An oncoprotein with many hands. Oncotarget. 5:4581–4602.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Böckelman C, Lassus H, Hemmes A, Leminen
A, Westermarck J, Haglund C, Bützow R and Ristimäki A: Prognostic
role of CIP2A expression in serous ovarian cancer. Br J Cancer.
105:989–995. 2011. View Article : Google Scholar :
|
|
18
|
Yeh E, Cunningham M, Arnold H, Chasse D,
Monteith T, Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S, Uchida
T, et al: A signaling pathway controlling c-Myc degradation that
impacts oncogenic transformation of human cells. Nat Cell Biol.
6:308–318. 2004. View
Article : Google Scholar : PubMed/NCBI
|
